8results about How to "Reduce apoptosis" patented technology

This invention belongs to the field of medical technology, specifically relating to the application of mitochondrial transplantation to regulate the immune-metabolic network in the treatment of myocardial dysfunction after cardiac arrest. The mitochondrial transplantation is performed within 0.5-2 hours after the restoration of spontaneous cardiac circulation. This technical solution, through multi-omics integrated analysis, proposes that mitochondrial transplantation exerts a cardioprotective effect by regulating the immune-metabolic-mitochondrial triaxial synergistic network, providing a new research direction for the precision treatment of myocardial dysfunction after cardiac arrest.

This invention relates to the field of cell biology, specifically to a co-culture cell model and method for primary glial cells and neurons. The method for co-culturing primary glial cells and neurons provided by this invention includes the following steps: a mixture of primary glial cells and neurons is seeded into a first co-culture medium for pre-culture; the medium is discarded and the cells are washed; a second co-culture medium is added for a first-stage culture; after the first-stage culture, a second-stage culture is performed; the medium used in the second-stage culture is a third co-culture medium supplemented with macrophage colony-stimulating factor; after the second-stage culture, a third-stage culture is performed; the medium used in the third-stage culture is the second co-culture medium; in the obtained co-culture cell model, microglia are differentiated and mature, and are in a quiescent state, thus obtaining a primary glial cell and neuron co-culture model.

The application provides application of a CSRNP1 inhibitor in preparation of a medicine for treating liver ischemia-reperfusion injury. The application further clarifies a molecular mechanism in which CSRNP1 improves hepatocyte injury by targeting a MAPK signaling pathway mediated cell apoptosis in the process of ischemia-reperfusion, and provides a new treatment strategy for reducing ischemia-reperfusion injury in a liver surgery process, by deeply analyzing expression changes of CSRNP1 in the process of liver ischemia-reperfusion and correlation between the expression changes and ischemia-reperfusion injury caused by a liver surgery.

This invention belongs to the field of microbial application technology, specifically relating to a method for preparing fermented *Lactobacillus limnoxicamis* extracellular vesicles, the product, and its applications, particularly the application of these fermented *Lactobacillus limnoxicamis* extracellular vesicles and their lyophilized formulations in the preparation of products with antioxidant or anti-aging effects. In this invention, *Lactobacillus limnoxicamis* is inoculated into a modified extracellular vesicle induction medium for fermentation. After culture, a two-stage solid-liquid separation is performed, and the supernatant is collected to obtain the extracellular vesicle processing solution. This solution is purified using a capillary electrophoresis system, and the positive extreme liquid is collected and filtered to obtain the purified product of fermented *Lactobacillus limnoxicamis* extracellular vesicles. The extracellular vesicles derived from fermented *Lactobacillus limnoxicamis* prepared by this invention can effectively scavenge free radicals. Somatic cell experiments have demonstrated its excellent anti-aging properties, and the transformation and application research of *Lactobacillus* extracellular vesicles has explored its development potential in the field of anti-aging products.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

This invention belongs to the field of functional microbial technology, specifically relating to a fermented *Lactobacillus rimoxifer* and its application in anti-aging. The fermented *Lactobacillus rimoxifer* F-B9-1-2 and its culture provided by this invention exhibit significant in vitro antioxidant capacity. A 0.5 mg / mL culture showed a scavenging rate of 89.3±2.1% for ABTS free radicals, demonstrating its antioxidant efficacy by reducing free radical damage to cells and maintaining normal cell function. Furthermore, treatment with its culture reduced the SA-β-gal positive cell rate from 12.8% to 7.1%, exhibiting good in vivo antioxidant activity, thus helping to inhibit or alleviate the aging process.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

This invention discloses the use of *Physalis alkekengi* oil in the preparation of drugs for the prevention and / or treatment of neurodegenerative diseases, belonging to the field of biomedical technology. The *Physalis alkekengi* oil of this invention is obtained by supercritical CO2 extraction, containing 2.16 g / 100g of EPA, 0.0104 g / 100g of nervonic acid, and a total unsaturated fatty acid content of 49.1 g / 100g. *Physalis alkekengi* oil exerts neuroprotective effects through multiple pathways, including inhibiting β-amyloid protein deposition, reducing neuronal apoptosis, alleviating neuroinflammation, and protecting dopaminergic neurons. It can effectively counteract neuronal damage caused by excitotoxicity and oxidative stress, significantly improve spatial learning and memory abilities, and alleviate cognitive decline. This invention provides a highly efficient and safe drug option for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.